FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597924427> ?p ?o ?g. }

• W2597924427 abstract "e20512 Background: HCM, caused primarily by tumor-induced bone resorption, is treated with intravenous (IV) bisphosphonates (BisP), but patients (pts) can relapse or become refractory. Denosumab binds to RANK ligand (RANKL) to inhibit osteoclast-mediated bone resorption. Methods: In this single-arm, open-label, proof-of-concept study, pts with HCM (corrected serum calcium [CSC] >12.5 mg/dL [CTCAE grade ≥3]) despite IV BisP treatment ≥7 and ≤30 days before screening received subcutaneous denosumab 120 mg on days 1, 8, 15, and 28, then every 4 weeks. The primary endpoint was the proportion of pts with CSC ≤11.5 mg/dL (CTCAE grade ≤1) within 10 days of denosumab initiation. Results: The study enrolled33 pts (64% men; mean age 60 years; 76% with advanced solid tumors, 39% with bone metastases [BM]), with a median (25 th , 75 th percentile [Q1, Q3]) follow-up of 56 (18, 79) days. Median (Q1, Q3) baseline CSC was 13.7 (13.2, 14.2) mg/dL; 19 pts (58%) had HCM symptoms. Median (Q1, Q3) time from last BisP treatment to first dose was 17 (13, 22) days. At day 10, 21 pts (64%) reached CSC ≤11.5 mg/dL, including 54% of pts with BM and 70% without BM. Over the course of the study, 23 pts (70%) reached CSC ≤11.5 mg/dL, by a median (95% confidence interval [CI]) of 9 (5–19) days. A complete response (CSC ≤10.8 mg/dL, as defined by previous studies) occurred in 12 pts (36%) at day 10, and in 21 pts (64%) during the study, by a median (95% CI) of 23 (11–43) days. Among pts who reached CSC ≤11.5 mg/dL, the median (95% CI) duration of response was 104 (9–not estimable) days. The most frequently reported serious adverse events were worsening of HCM (5 pts, 15%) and dyspnea (3 pts, 9%). Two pts had isolated episodes of CSC levels ≤8.0 mg/dL (CTCAE grade 2); no pts had CSC <7.0 mg/dL (grade 3). No osteonecrosis of the jaw was reported. Conclusions: In this study of pts with HCM despite recent IV BisP treatment, denosumab effectively lowered serum calcium to grade ≤1 in 64% of pts within 10 days, and induced durable responses. These findings are particularly meaningful given that pts entered this study with grade ≥3 HCM within a median 17 days after receiving IV BisP. No unexpected safety findings were identified. Denosumab may offer a new treatment option for HCM in these pts. Clinical trial information: NCT00896454." @default.
• W2597924427 created "2017-04-07" @default.
• W2597924427 creator A5009418529 @default.
• W2597924427 creator A5026625329 @default.
• W2597924427 creator A5034878356 @default.
• W2597924427 creator A5038456224 @default.
• W2597924427 creator A5044778501 @default.
• W2597924427 creator A5045531429 @default.
• W2597924427 creator A5045554018 @default.
• W2597924427 creator A5059248910 @default.
• W2597924427 creator A5059367989 @default.
• W2597924427 creator A5062112339 @default.
• W2597924427 creator A5081409867 @default.
• W2597924427 creator A5083249739 @default.
• W2597924427 creator A5084109000 @default.
• W2597924427 creator A5088108970 @default.
• W2597924427 creator A5091000505 @default.
• W2597924427 date "2013-05-20" @default.
• W2597924427 modified "2023-09-26" @default.
• W2597924427 title "Denosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM)." @default.
• W2597924427 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.e20512" @default.
• W2597924427 hasPublicationYear "2013" @default.
• W2597924427 type Work @default.
• W2597924427 sameAs 2597924427 @default.
• W2597924427 citedByCount "0" @default.
• W2597924427 crossrefType "journal-article" @default.
• W2597924427 hasAuthorship W2597924427A5009418529 @default.
• W2597924427 hasAuthorship W2597924427A5026625329 @default.
• W2597924427 hasAuthorship W2597924427A5034878356 @default.
• W2597924427 hasAuthorship W2597924427A5038456224 @default.
• W2597924427 hasAuthorship W2597924427A5044778501 @default.
• W2597924427 hasAuthorship W2597924427A5045531429 @default.
• W2597924427 hasAuthorship W2597924427A5045554018 @default.
• W2597924427 hasAuthorship W2597924427A5059248910 @default.
• W2597924427 hasAuthorship W2597924427A5059367989 @default.
• W2597924427 hasAuthorship W2597924427A5062112339 @default.
• W2597924427 hasAuthorship W2597924427A5081409867 @default.
• W2597924427 hasAuthorship W2597924427A5083249739 @default.
• W2597924427 hasAuthorship W2597924427A5084109000 @default.
• W2597924427 hasAuthorship W2597924427A5088108970 @default.
• W2597924427 hasAuthorship W2597924427A5091000505 @default.
• W2597924427 hasConcept C121332964 @default.
• W2597924427 hasConcept C121608353 @default.
• W2597924427 hasConcept C126322002 @default.
• W2597924427 hasConcept C142424586 @default.
• W2597924427 hasConcept C143998085 @default.
• W2597924427 hasConcept C2776286101 @default.
• W2597924427 hasConcept C2776541429 @default.
• W2597924427 hasConcept C2776886416 @default.
• W2597924427 hasConcept C2777251235 @default.
• W2597924427 hasConcept C2779399171 @default.
• W2597924427 hasConcept C2781064419 @default.
• W2597924427 hasConcept C2911223091 @default.
• W2597924427 hasConcept C71924100 @default.
• W2597924427 hasConcept C87355193 @default.
• W2597924427 hasConceptScore W2597924427C121332964 @default.
• W2597924427 hasConceptScore W2597924427C121608353 @default.
• W2597924427 hasConceptScore W2597924427C126322002 @default.
• W2597924427 hasConceptScore W2597924427C142424586 @default.
• W2597924427 hasConceptScore W2597924427C143998085 @default.
• W2597924427 hasConceptScore W2597924427C2776286101 @default.
• W2597924427 hasConceptScore W2597924427C2776541429 @default.
• W2597924427 hasConceptScore W2597924427C2776886416 @default.
• W2597924427 hasConceptScore W2597924427C2777251235 @default.
• W2597924427 hasConceptScore W2597924427C2779399171 @default.
• W2597924427 hasConceptScore W2597924427C2781064419 @default.
• W2597924427 hasConceptScore W2597924427C2911223091 @default.
• W2597924427 hasConceptScore W2597924427C71924100 @default.
• W2597924427 hasConceptScore W2597924427C87355193 @default.
• W2597924427 hasLocation W25979244271 @default.
• W2597924427 hasOpenAccess W2597924427 @default.
• W2597924427 hasPrimaryLocation W25979244271 @default.
• W2597924427 hasRelatedWork W1466641609 @default.
• W2597924427 hasRelatedWork W1923732536 @default.
• W2597924427 hasRelatedWork W1963512072 @default.
• W2597924427 hasRelatedWork W1967893206 @default.
• W2597924427 hasRelatedWork W2108844864 @default.
• W2597924427 hasRelatedWork W2120844609 @default.
• W2597924427 hasRelatedWork W2228825113 @default.
• W2597924427 hasRelatedWork W2274920823 @default.
• W2597924427 hasRelatedWork W2304731873 @default.
• W2597924427 hasRelatedWork W2405423385 @default.
• W2597924427 hasRelatedWork W2408969568 @default.
• W2597924427 hasRelatedWork W2622332681 @default.
• W2597924427 hasRelatedWork W2804877339 @default.
• W2597924427 hasRelatedWork W2808167262 @default.
• W2597924427 hasRelatedWork W2921585311 @default.
• W2597924427 hasRelatedWork W2956018153 @default.
• W2597924427 hasRelatedWork W3005182510 @default.
• W2597924427 hasRelatedWork W3092944678 @default.
• W2597924427 hasRelatedWork W3117155022 @default.
• W2597924427 hasRelatedWork W3214272523 @default.
• W2597924427 isParatext "false" @default.
• W2597924427 isRetracted "false" @default.
• W2597924427 magId "2597924427" @default.
• W2597924427 workType "article" @default.